Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 28, 2026, 7:05 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 66 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Placebo (for Pregabalin) Clear all
Terminated Phase 4 Interventional Results available

Preemptive Analgesia Following Uterine Artery Embolization

NCT01555073
View directory record Official record
Conditions
Uterine Fibroids, Uterine Artery Embolization
Interventions
pregabalin/celecoxib, pregabalin/placebo, celecoxib/placebo, Placebo group
Drug
Lead sponsor
Northwestern University
Other
Eligibility
18 Years to 65 Years · Female only
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jul 27, 2016 · Synced Sep 28, 2026, 7:05 AM EDT
Completed Phase 3 Interventional Results available

Treatment of Pain Associated With Fibromyalgia

NCT02187471
View directory record Official record
Conditions
Pain Associated With Fibromyalgia
Interventions
DS-5565, Pregabalin, Placebo tablet, Placebo capsule
Drug
Lead sponsor
Daiichi Sankyo
Industry
Eligibility
18 Years and older
Enrollment
1,301 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
91
States / cities
Birmingham, Alabama • Huntsville, Alabama • Phoenix, Arizona + 87 more
Source: ClinicalTrials.gov public record
Updated Nov 8, 2020 · Synced Sep 28, 2026, 7:05 AM EDT
Completed Phase 2 Interventional

A Multicenter Study Comparing the Analgesic Effects and Safety of ABT-639 Compared to Placebo in Subjects With Diabetic Neuropathic Pain

NCT01345045
View directory record Official record
Conditions
Diabetic Neuropathic Pain
Interventions
ABT-639, pregabalin, Placebo
Drug
Lead sponsor
AbbVie (prior sponsor, Abbott)
Industry
Eligibility
18 Years to 75 Years
Enrollment
193 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011
U.S. locations
19
States / cities
Little Rock, Arkansas • Anaheim, California • Long Beach, California + 15 more
Source: ClinicalTrials.gov public record
Updated Jan 7, 2013 · Synced Sep 28, 2026, 7:05 AM EDT
Completed Phase 3 Interventional Results available

Study Of The Efficacy And Safety Of Pregabalin Compared To Placebo For Treatment Of Post-Surgical Pain From Hysterectomy

NCT00468845
View directory record Official record
Conditions
Pain, Postoperative
Interventions
pregabalin (Lyrica), matched placebo
Drug
Lead sponsor
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Industry
Eligibility
25 Years to 70 Years · Female only
Enrollment
501 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
14
States / cities
Mobile, Alabama • Glendale, Arizona • Phoenix, Arizona + 6 more
Source: ClinicalTrials.gov public record
Updated Feb 9, 2021 · Synced Sep 28, 2026, 7:05 AM EDT
Completed Phase 2 Interventional Results available

A Placebo-Controlled Trial of Pregabalin (Lyrica) for Irritable Bowel Syndrome

NCT00977197
View directory record Official record
Conditions
Irritable Bowel Syndrome
Interventions
Pregabalin, Placebo
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years to 70 Years
Enrollment
85 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2015
U.S. locations
2
States / cities
Rochester, Minnesota • La Crosse, Wisconsin
Source: ClinicalTrials.gov public record
Updated Oct 27, 2016 · Synced Sep 28, 2026, 7:05 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Pregabalin in Treating Women With Hot Flashes

NCT00702949
View directory record Official record
Conditions
Breast Cancer, Hot Flashes
Interventions
pregabalin, placebo
Drug · Other
Lead sponsor
Alliance for Clinical Trials in Oncology
Other
Eligibility
18 Years and older · Female only
Enrollment
207 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2015
U.S. locations
209
States / cities
Scottsdale, Arizona • Aurora, Colorado • Boulder, Colorado + 135 more
Source: ClinicalTrials.gov public record
Updated Jul 31, 2016 · Synced Sep 28, 2026, 7:05 AM EDT
Terminated Phase 2 Interventional Results available

Study to Assess the Efficacy, Safety, and Tolerability of ADL5747 in Participants With Postherpetic Neuralgia

NCT01058642
View directory record Official record
Conditions
Postherpetic Neuralgia
Interventions
ADL5747, Placebo, Pregabalin
Drug
Lead sponsor
Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Industry
Eligibility
18 Years to 75 Years
Enrollment
41 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010
U.S. locations
1
States / cities
West Palm Beach, Florida
Source: ClinicalTrials.gov public record
Updated Jul 29, 2015 · Synced Sep 28, 2026, 7:05 AM EDT
Terminated Phase 2 Interventional Results available

Research Examining Gulf War Illness in Our Nations Service Members

NCT01846182
View directory record Official record
Conditions
Gulf War Illness
Interventions
Duloxetine, Pregabalin, Placebo
Drug
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
44 Years to 70 Years
Enrollment
112 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
2
States / cities
Temple, Texas • Waco, Texas
Source: ClinicalTrials.gov public record
Updated Mar 11, 2021 · Synced Sep 28, 2026, 7:05 AM EDT
Completed Phase 2 Interventional Results available

Treatment of Neuropathic Pain Associated With Diabetic Peripheral Neuropathy

NCT01496365
View directory record Official record
Conditions
Diabetic Peripheral Neuropathy
Interventions
DS-5565 tablet, pregabalin capsule, Placebo tablet, placebo capsule
Drug
Lead sponsor
Daiichi Sankyo
Industry
Eligibility
18 Years and older
Enrollment
452 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
78
States / cities
Birmingham, Alabama • Huntsville, Alabama • Mesa, Arizona + 66 more
Source: ClinicalTrials.gov public record
Updated Jan 4, 2021 · Synced Sep 28, 2026, 7:05 AM EDT
Recruiting Phase 2 Interventional Accepts healthy volunteers

Pregabalin Plus Lofexidine for the Outpatient Treatment of Opioid Withdrawal

NCT05995535
View directory record Official record
Conditions
Opiate Withdrawal Syndrome, Opioid Use
Interventions
LFX/PGB, LFX/PLA-PGB
Drug
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years and older
Enrollment
150 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2026
U.S. locations
2
States / cities
Baltimore, Maryland • Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Feb 12, 2026 · Synced Sep 28, 2026, 7:05 AM EDT
Recruiting Phase 3 Interventional

Evaluation of Efficacy and Safety of Suzetrigine for Pain Associated With Diabetic Peripheral Neuropathy

NCT06628908
View directory record Official record
Conditions
Diabetic Peripheral Neuropathic Pain
Interventions
Suzetrigine, Placebo (matched to SUZ), Pregabalin, Placebo (matched to Pregabalin)
Drug
Lead sponsor
Vertex Pharmaceuticals Incorporated
Industry
Eligibility
18 Years to 80 Years
Enrollment
1,100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
76
States / cities
Anniston, Alabama • Birmingham, Alabama • Daphne, Alabama + 68 more
Source: ClinicalTrials.gov public record
Updated Jun 14, 2026 · Synced Sep 28, 2026, 7:05 AM EDT
Completed Phase 2 Interventional Results available

Evaluation of Efficacy and Safety of VX-548 for Painful Diabetic Peripheral Neuropathy (DPN)

NCT05660538
View directory record Official record
Conditions
Diabetic Peripheral Neuropathy
Interventions
Suzetrigine, Pregabalin, Placebo (matched to SUZ), Placebo (matched to pregabalin)
Drug
Lead sponsor
Vertex Pharmaceuticals Incorporated
Industry
Eligibility
18 Years to 80 Years
Enrollment
194 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
50
States / cities
Anniston, Alabama • Birmingham, Alabama • Phoenix, Arizona + 47 more
Source: ClinicalTrials.gov public record
Updated Jun 30, 2025 · Synced Sep 28, 2026, 7:05 AM EDT
Completed Phase 3 Interventional Results available

A Phase 3b Multicenter Study of Pregabalin in Fibromyalgia Subjects Who Have Comorbid Depression

NCT01432236
View directory record Official record
Conditions
Fibromyalgia
Interventions
Pregabalin, placebo
Drug
Lead sponsor
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Industry
Eligibility
18 Years and older
Enrollment
197 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
26
States / cities
Tucson, Arizona • Orange, California • Santa Ana, California + 21 more
Source: ClinicalTrials.gov public record
Updated Jan 21, 2021 · Synced Sep 28, 2026, 7:05 AM EDT
Completed Phase 2 Interventional Results available

A Study for Treatment of Pain in Patients With Diabetic Neuropathy.

NCT00785577
View directory record Official record
Conditions
Diabetic Neuropathy, Painful
Interventions
Placebo, Pregabalin, LY545694 21 mg, LY545694 49 mg, LY545694 105 mg
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years to 70 Years
Enrollment
273 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
8
States / cities
Greenbrae, California • Tustin, California • DeLand, Florida + 5 more
Source: ClinicalTrials.gov public record
Updated May 30, 2012 · Synced Sep 28, 2026, 7:05 AM EDT
Completed Phase 2Phase 3 Interventional Accepts healthy volunteers Results available

Can Pregabalin Reduce the Frequency and Severity of Dry Eye Symptoms After Laser-assisted in Situ Keratomileusis?

NCT02701764
View directory record Official record
Conditions
Dry Eye
Interventions
Pregabalin, Placebo
Drug
Lead sponsor
University of Miami
Other
Eligibility
18 Years to 65 Years
Enrollment
43 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2018
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Nov 13, 2019 · Synced Sep 28, 2026, 7:05 AM EDT
Terminated Phase 2 Interventional Results available

Pregabalin for the Treatment of Vulvodynia

NCT00853229
View directory record Official record
Conditions
Vulvodynia, Vulvar Vestibulitis
Interventions
pregabalin
Drug
Lead sponsor
The Cleveland Clinic
Other
Eligibility
18 Years and older · Female only
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2013
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Jul 18, 2021 · Synced Sep 28, 2026, 7:05 AM EDT
Completed Phase 3 Interventional Results available

Effect Of Pregabalin Treatment In Patients With Diabetic Nerve Pain Who Currently Use A Non-Steroid Anti-Inflammatory Drug (NSAID) For Another Pain

NCT01455415
View directory record Official record
Conditions
Painful Diabetic Peripheral Neuropathy
Interventions
pregabalin, placebo
Drug
Lead sponsor
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Industry
Eligibility
18 Years and older
Enrollment
306 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
55
States / cities
Goodyear, Arizona • Phoenix, Arizona • Tucson, Arizona + 38 more
Source: ClinicalTrials.gov public record
Updated Jan 27, 2021 · Synced Sep 28, 2026, 7:05 AM EDT
Completed Phase 3 Interventional Results available

Efficacy & Safety Study of Pregabalin to Treat Chronic Prostatitis/Chronic Pelvic Pain Syndrome (CP/CPPS)

NCT00371033
View directory record Official record
Conditions
Chronic Prostatitis/Chronic Pelvic Pain Syndrome (CP/CPPS)
Interventions
Pregabalin, Placebo
Drug
Lead sponsor
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NIH
Eligibility
18 Years and older · Male only
Enrollment
324 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
10
States / cities
Los Angeles, California • Stanford, California • Chicago, Illinois + 6 more
Source: ClinicalTrials.gov public record
Updated Sep 21, 2025 · Synced Sep 28, 2026, 7:05 AM EDT
Completed Phase 3 Interventional

A Study of the Efficacy and Safety of Pregabalin for the Treatment of Fibromyalgia

NCT00645398
View directory record Official record
Conditions
Fibromyalgia
Interventions
Pregabalin, Placebo
Drug
Lead sponsor
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Industry
Eligibility
18 Years and older
Enrollment
751 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2005
U.S. locations
102
States / cities
Birmingham, Alabama • Huntsville, Alabama • Paradise Valley, Arizona + 81 more
Source: ClinicalTrials.gov public record
Updated Jan 24, 2021 · Synced Sep 28, 2026, 7:05 AM EDT
Terminated Phase 4 Interventional Results available

Pregabalin for Abdominal Pain From Adhesions

NCT00310765
View directory record Official record
Conditions
Abdominal Pain, Surgical Adhesions
Interventions
Pregabalin 75 or 150 mg BID for 7 weeks followed by open label pregabalin 150 mg BID for 4 weeks, Placebo first followed by open label pregabalin
Drug
Lead sponsor
Henry Ford Health System
Other
Eligibility
18 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
1
States / cities
West Bloomfield, Michigan
Source: ClinicalTrials.gov public record
Updated Oct 22, 2023 · Synced Sep 28, 2026, 7:05 AM EDT
Completed Phase 3 Interventional Results available

Treatment of Pain Associated With Fibromyalgia

NCT02187159
View directory record Official record
Conditions
Pain Associated With Fibromyalgia
Interventions
DS-5565, Pregabalin, Placebo tablet, Placebo capsule
Drug
Lead sponsor
Daiichi Sankyo
Industry
Eligibility
18 Years and older
Enrollment
1,270 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
86
States / cities
Mobile, Alabama • Phoenix, Arizona • Scottsdale, Arizona + 81 more
Source: ClinicalTrials.gov public record
Updated Nov 8, 2020 · Synced Sep 28, 2026, 7:05 AM EDT
Completed Phase 3 Interventional Results available

Placebo-controlled Safety and Efficacy Study of Pregabalin in Subjects With Post-traumatic Peripheral Neuropathic Pain

NCT01701362
View directory record Official record
Conditions
Neuropathic Pain
Interventions
pregabalin, placebo
Drug
Lead sponsor
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Industry
Eligibility
18 Years and older
Enrollment
542 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
105
States / cities
Huntsville, Alabama • Goodyear, Arizona • Phoenix, Arizona + 70 more
Source: ClinicalTrials.gov public record
Updated Jan 27, 2021 · Synced Sep 28, 2026, 7:05 AM EDT
Completed Not applicable Interventional Results available

A Comparison of Pregabalin (Lyrica®) to Placebo in Pain Relief After Photorefractive Keratectomy (PRK) Surgery

NCT01097577
View directory record Official record
Conditions
Postoperative Pain
Interventions
pregabalin, Placebo
Drug
Lead sponsor
59th Medical Wing
Federal
Eligibility
21 Years and older
Enrollment
130 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010
U.S. locations
1
States / cities
Lackland Air Force Base, Texas
Source: ClinicalTrials.gov public record
Updated Oct 27, 2020 · Synced Sep 28, 2026, 7:05 AM EDT
Terminated Phase 2 Interventional Accepts healthy volunteers

Study to Find Out if Therapy With the Drug Pregabalin Relieves Pain During Shingles Compared With Placebo

NCT00352651
View directory record Official record
Conditions
Herpes Zoster, Postherpetic Neuralgia
Interventions
Pregabalin
Drug
Lead sponsor
University of California, San Francisco
Other
Eligibility
21 Years to 80 Years
Enrollment
34 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Apr 13, 2011 · Synced Sep 28, 2026, 7:05 AM EDT